Pain: A potential new label of COVID-19

Abstract

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Fig. 1. The potential mechanism of pain induced by SARS-CoV-2 in COVID-19.

COVID-19: Pain Management in Patients with SARS-CoV-2 Infection—Molecular Mechanisms, Challenges, and Perspectives

“…II (Angiotensin II) and the decrease of Ang. (1–7) (Angiotensin 1–7) [ 31 ]. The pain induced by COVID-19 infection could result from the effect of spinal ACE2 on pain sensation and the direct or indirect tissue damage, but the ACE2 role in the transmission and management of pain in infected patients needs further investigation [ 31 ].…”

SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia

“… 14 , 41 Pain is a rising concern in symptomatic patients, likely emanating from a direct attack of SARS-CoV-2 on cells and the “cytokine storm” unleashed by affected cells. 51 , 67 Whether asymptomatic or minimally symptomatic individuals have reduced pain thresholds, or whether their pain is silenced is unknown, but either could contribute to increased disease transmission dynamics.…”

Pain related viral infections: a literature review

“…Reports of neurological sequelae after COVID-19 infection is increasing by the time associated with the involvement of ACE2 receptor in the neural tissue. Based on these reports, COVID-19 infection could manifest as painful symptoms that require pain medications [ 24 , 25 ].…”

“…The management of this manifestations is similar with another viral infection: symptomatic therapy depends on the symptoms occurred in patients. Further research is needed to understand how the SARS-CoV-2 could damage and impact musculoskeletal systems [ 24 , 25 ]. There is no specific treatment to treat COVID-19 as the researches for this infection is still on going.…”